Real-world health utility scores and toxicities to tyrosine kinase inhibitors in epidermal growth factor receptor mutated advanced non-small cell lung cancer.

ABSTRACT:

Background

As the treatment landscape in patients with non-small cell lung cancer (NSCLC) harboring mutations in the epidermal growth factor receptor (EGFRm) continues to evolve, real-world health utility scores (HUS) become increasingly important for economic analyses.

Methods

In an observational cohort study, questionnaires were completed in EGFRm NSCLC outpatients, to include demographics, EQ-5D-based HUS and patient-reported toxicity and symptoms. Clinical and radiologic characteristics together with outcomes were extracted from chart review. The impact of health states, treatment type, toxicities, and clinical variables on HUS were evaluated.

Results

Between 2014 and 2018, a total of 260 patients completed 994 encounters. Across treatment groups, patients with di

SUBMITTER: Jiang SX 

PROVIDER: S-EPMC6912023 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature